Analysts Offer Predictions for Affimed NV’s FY2019 Earnings (NASDAQ:AFMD)

Affimed NV (NASDAQ:AFMD) – Equities researchers at Jefferies Financial Group decreased their FY2019 earnings estimates for Affimed in a research report issued to clients and investors on Tuesday, November 19th. Jefferies Financial Group analyst M. Raycroft now forecasts that the biopharmaceutical company will post earnings of ($0.61) per share for the year, down from their prior forecast of $0.29. Jefferies Financial Group also issued estimates for Affimed’s Q4 2019 earnings at ($0.25) EPS, FY2020 earnings at ($0.34) EPS, FY2021 earnings at $0.07 EPS, FY2022 earnings at $1.14 EPS and FY2023 earnings at ($0.73) EPS.

A number of other equities research analysts also recently weighed in on the stock. ValuEngine upgraded shares of Affimed from a “sell” rating to a “hold” rating in a research report on Wednesday, August 28th. Zacks Investment Research downgraded shares of Affimed from a “buy” rating to a “hold” rating in a research report on Thursday, August 8th. Two investment analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus price target of $6.36.

NASDAQ AFMD opened at $2.37 on Friday. The company has a current ratio of 3.48, a quick ratio of 3.47 and a debt-to-equity ratio of 0.02. Affimed has a 1-year low of $2.18 and a 1-year high of $5.08. The company has a 50 day moving average of $2.76 and a 200-day moving average of $2.98. The company has a market cap of $178.40 million, a price-to-earnings ratio of -6.24 and a beta of 2.91.

Affimed (NASDAQ:AFMD) last released its quarterly earnings results on Tuesday, November 19th. The biopharmaceutical company reported ($0.19) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.05). Affimed had a negative net margin of 25.43% and a negative return on equity of 26.26%. The business had revenue of $2.34 million during the quarter, compared to analyst estimates of $6.77 million.

Large investors have recently made changes to their positions in the stock. Canada Pension Plan Investment Board bought a new position in Affimed in the second quarter valued at approximately $574,000. Acadian Asset Management LLC grew its stake in shares of Affimed by 3,524.2% during the second quarter. Acadian Asset Management LLC now owns 2,176,604 shares of the biopharmaceutical company’s stock worth $6,247,000 after buying an additional 2,116,546 shares during the last quarter. BlackRock Inc. bought a new stake in shares of Affimed during the second quarter worth $8,399,000. Charles Schwab Investment Management Inc. bought a new stake in shares of Affimed during the second quarter worth $360,000. Finally, Meeder Asset Management Inc. bought a new stake in shares of Affimed during the third quarter worth $47,000. 47.93% of the stock is currently owned by institutional investors and hedge funds.

Affimed Company Profile

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Europe, and Germany. Its lead product candidate is AFM13, a natural killer cell (NK-cell) TandAb, which is in Phase 2a clinical study of relapsed CD30-positive lymphoma and Phase 1b clinical study of anti-PD-1 antibody Keytruda (pembrolizumab) in patients with relapsed Hodgkin lymphoma.

Featured Story: What is diluted earnings per share (Diluted EPS)?

Earnings History and Estimates for Affimed (NASDAQ:AFMD)

Receive News & Ratings for Affimed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Affimed and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit